Growth Hormone Treatment of Non-Growth Hormone-Deficient Growth Disorders

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 1, 2007, Pages 131-186

  Quigley, Charmian A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; MESSENGER RNA; OXANDROLONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATREM;

BODY HEIGHT; CARBOHYDRATE METABOLISM; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EDEMA; ESTROGEN THERAPY; FOOD AND DRUG ADMINISTRATION; GENE; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GROWTH DISORDER; GROWTH HORMONE RELEASE; GROWTH RATE; GYNECOMASTIA; HEARING IMPAIRMENT; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACRANIAL HYPERTENSION; KIDNEY FUNCTION; LEUKEMIA; LONG TERM CARE; MEDICAL SOCIETY; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OTITIS MEDIA; PANCREATITIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCOLIOSIS; SHORT STATURE; SHOX GENE; SIDE EFFECT; SMALL FOR DATE INFANT; TURNER SYNDROME;

BODY HEIGHT; GROWTH DISORDERS; GROWTH HORMONE; HOMEODOMAIN PROTEINS; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MODELS, BIOLOGICAL; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; TURNER SYNDROME;

EID: 33847348935     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.11.006     Document Type: Review

References (328)

1. Raben M.S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18 (1958) 901-903
2. Underwood L.E. Report of the conference on uses and possible abuses of biosynthetic human growth hormone. N Engl J Med 311 (1984) 606-608
3. American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. 1997. Considerations related to the use of recombinant human growth hormone in children. Pediatrics 1997;99:122-9.
4. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for growth hormone use in adults and children-2003 Update. Endocr Pract 2003;9:65-76.
5. Kuczmarski R.J., Ogden C.L., Grummer-Strawn L.M., et al. CDC growth charts: United States. Adv Data 8 (2000) 1-27
6. Allen D.B., and Fost N.C. Growth hormone therapy for short stature: panacea or Pandora's box?. J Pediatr 117 (1990) 16-21
7. Rosenfeld R.G., Albertsson-Wikland K., Cassorla F., et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 80 (1995) 1532-1540
8. Rosenfeld R.G. Is growth hormone deficiency a viable diagnosis?. J Clin Endocrinol Metab 82 (1997) 349-351
9. Bright G.M., Julius J.R., Lima J., et al. Growth hormone stimulation test results as predictors of recombinant human growth hormone treatment outcomes: preliminary analysis of the national cooperative growth study database. Pediatrics 104 (1999) 1028-1031
10. Saggese G., Ranke M.B., Saenger P., et al. Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten Years After the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27-28 March 1998. Horm Res 50 (1998) 320-340
11. Sizonenko P.C., Clayton P.E., Cohen P., et al. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: diagnosis of growth hormone deficiency. Growth Horm IGF Res 11 (2001) 137-165
12. Saenger P. Growth hormone in growth hormone deficiency. BMJ 325 (2002) 58-59
13. Badaru A., and Wilson D.M. Alternatives to growth hormone stimulation testing in children. Trends Endocrinol Metab 15 (2004) 252-258
14. Werther G.A., Wang M., and Cowell C.T. An auxology-based growth hormone program: update on the Australian experience. J Pediatr Endocrinol Metab 16 Suppl 3 (2003) 613-618
15. Hogler W., Briody J., Moore B., et al. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone 37 (2005) 642-650
16. Isaksson O., Jansson J., and Gause I. Growth hormone stimulates longitudinal bone growth directly. Science 216 (1982) 1237-1239
17. Isaksson O., Lindahl A., Nilsson A., et al. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 8 (1987) 426-438
18. Hokken-Koelega A.C., Stijnen T., De Jong M.C., et al. Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. J Clin Endocrinol Metab 79 4 (1994) 1185-1190
19. Carel J.C., Mathivon L., Gendrel C., et al. Near normalization of final height with adapted doses of growth hormone in Turner's syndrome. J Clin Endocrinol Metab 83 (1998) 1462-1466
20. Sas T.C., de Muinck Keizer-Schrama S.M., Stijnen T., et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 84 12 (1999) 4607-4612
21. Sas T., de Waal W., Mulder P., et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 84 9 (1999) 3064-3070
22. Lupu F., Terwilliger J.D., Lee K., et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 229 (2001) 141-162
23. van Teunenbroek A., de Muinck Keizer-Schrama S.M., Stijnen T., et al. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone. J Clin Endocrinol Metab 81 11 (1996) 4013-4021
24. Cohen P., Bright G.M., Rogol A.D., et al. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 87 (2002) 90-98
25. Kamp G.A., Zwinderman A.H., van D.J., et al. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol (Ox) 57 (2002) 315-325
26. Cohen P, Weng W, Kappelgaard AM, et al. Multivariate analysis of height outcome from an IGF-1 based GH trial in children with short stature. Abstract OR32-3 presented at the 88th annual meeting of the Endocrine Society. Boston, June 24-27, 2006.
27. van Pareren Y.K., de Muinck Keizer-Schrama S.M., Stijnen T., et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 88 (2003) 1119-1125
28. van Pareren Y., Mulder P., Houdijk M., et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 88 8 (2003) 3584-3590
29. Dos Santos C., Essioux L., Teinturier C., et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36 7 (2004) 720-724
30. Warady B.A. Growth retardation in children with chronic renal insufficiency. J Am Soc Nephrol 9 (1998) S85-S89
31. Ardissino G., Dacco V., Testa S., et al., for the ItalKid Project. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111 4 Pt 1 (2003) e382-e387
32. Furth S.L. Growth and nutrition in children with chronic kidney disease. Adv Chronic Kidney Dis 12 4 (2005) 366-371
33. Furth S.L., Stablein D., Fine R.N., et al. Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 109 5 (2002) 909-913
34. Betts P.R., Magrath G., and White R.H. Role of dietary energy supplementation in growth of children with chronic renal insufficiency. BMJ 1 (1977) 416-418
35. Tonshoff B, Mehls O. Growth retardation in children with chronic renal disease - pathophysiology and treatment. In: Hindmarsh PC, editor. Current indications for growth hormone therapy. 1st edition. Basel: Karger; 1999. p. 128-56.
36. Schaefer F., Seidel C., Binding A., et al. Pubertal growth in chronic renal failure. Pediatr Res 28 1 (1990) 5-10
37. Scharer K. Growth and development of children with chronic renal failure. Study Group on Pubertal Development in Chronic Renal Failure. Acta Paediatr Scand Suppl 366 (1990) 90-92
38. Vimalachandra D., Hodson E.M., Willis N.S., et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 3 (2001) CD003264
39. Perrone L., Sinisi A.A., Criscuolo T., et al. Plasma and urinary growth hormone and insulin-like growth factor I in children with chronic renal insufficiency. Child Nephrol Urol 10 2 (1990) 72-75
40. Kohaut E.C. Chronic renal disease and growth in childhood. Curr Opin Pediatr 7 2 (1995) 171-175
41. Fine R.N. Growth hormone and the kidney: the use of recombinant human growth hormone (rhGH) in growth-retarded children with chronic renal insufficiency. J Am Soc Nephrol 1 10 (1991) 1136-1145
42. Haffner D., Schaefer F., Girard J., et al. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest 93 3 (1994) 1163-1171
43. Schaefer F., Veldhuis J.D., Stanhope R., et al. Alterations in growth hormone secretion and clearance in peripubertal boys with chronic renal failure and after renal transplantation. Cooperative Study Group of Pubertal development in Chronic Renal Failure. J Clin Endocrinol Metab 78 6 (1994) 1298-1306
44. Tonshoff B., Veldhuis J.D., Heinrich U., et al. Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease. Pediatr Res 37 (1995) 86-93
45. Lanes R. Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol 3 (2004) 53-66
46. Postel-Vinay M.C., Tar A., Crosnier H., et al. Plasma growth hormone-binding activity is low in uraemic children. Pediatr Nephrol 5 (1991) 545-547
47. Baumann G. Growth hormone binding protein and free growth hormone in chronic renal failure. Pediatr Nephrol 10 3 (1996) 328-330
48. Tonshoff B., Cronin M.J., Reichert M., et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Clin Endocrinol Metab 82 (1997) 1007-1013
49. Rabkin R., Sun D.F., Chen Y., et al. Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 20 3 (2005) 313-318
50. Tonshoff B., Blum W.F., Wingen A.M., et al. Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Clin Endocrinol Metab 80 (1995) 2684-2691
51. Powell D.R., Liu F., Baker B.K., et al. Insulin-like growth factor-binding protein-6 levels are elevated in serum of children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 82 (1997) 2978-2984
52. Durham S.K., Mohan S., Liu F., et al. Bioactivity of a 29-kilodalton insulin-like growth factor binding protein-3 fragment present in excess in chronic renal failure serum. Pediatr Res 42 (1997) 335-341
53. Koch V.H., Lippe B.M., Nelson P.A., et al. Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr 115 3 (1989) 365-371
54. Rees L., Rigden S.P., Ward G., et al. Treatment of short stature in renal disease with recombinant human growth hormone. Arch Dis Child 65 (1990) 856-860
55. Tonshoff B., Mehls O., Heinrich U., et al. Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease. J Pediatr 116 (1990) 561-566
56. Fine R.N., Pyke-Grimm K., Nelson P.A., et al. Recombinant human growth hormone treatment of children with chronic renal failure: long-term (1- to 3-year) outcome. Pediatr Nephrol 5 (1991) 477-481
57. Hokken-Koelega A.C., Stijnen T., de Muinck Keizer-Schrama S.M., et al. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 338 8767 (1991) 585-590
58. Berard E., Crosnier H., Six-Beneton A., et al. Recombinant human growth hormone treatment of children on hemodialysis. French Society of Pediatric Nephrology. Pediatr Nephrol 12 4 (1998) 304-310
59. Fine R.N., Kohaut E.C., Brown D., et al. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatr 124 (1994) 374-382
60. Powell D.R., Liu F., Baker B.K., et al. Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group. Kidney Int 51 6 (1997) 1970-1979
61. Nutropin (somatropin [rDNA origin] for injection). [prescribing information] (2006), Genentech Inc., South San Francisco (CA)
62. Fine R.N., Sullivan E.K., and Tejani A. The impact of recombinant human growth hormone treatment on final adult height. Pediatr Nephrol 14 (2000) 679-681
63. Hokken-Koelega A., Mulder P., De Jong R., et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 14 7 (2000) 701-706
64. Fine R.N., Brown D.F., Kuntze J., et al. Growth after discontinuation of recombinant human growth hormone therapy in children with chronic renal insufficiency. The Genentech Cooperative Study Group. J Pediatr 129 6 (1996) 883-891
65. Haffner D., and Schaefer F. Does recombinant growth hormone improve adult height in children with chronic renal failure?. Semin Nephrol 21 5 (2001) 490-497
66. Crompton C.H. Australian and New Zealand Paediatric Nephrology Association. Long-term recombinant human growth hormone use in Australian children with renal disease. Nephrol 9 5 (2004) 325-330
67. Fine R.N., Ho M., Tejani A., et al. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediatr 142 5 (2003) 539-545
68. Lanes R., Gunczler P., Orta N., et al. Changes in bone mineral density, growth velocity and renal function of prepubertal uremic children during growth hormone treatment. Horm Res 46 6 (1996) 263-268
69. Broyer M. Results and side-effects of treating children with growth hormone after kidney transplantation-a preliminary report. Pharmacia & Upjohn Study Group. Acta Paediatr Suppl 417 (1996) 76-79
70. Hokken-Koelega A.C. Growth hormone treatment in children before and after renal transplantation. J Pediatr Endocrinol 9 Suppl 3 (1996) 359-364
71. Guest G., Berard E., Crosnier H., et al. Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Pediatr Nephrol 12 6 (1998) 437-446
72. Tonshoff B., and Mehls O. Use of rhGH posttransplanation in children. In: Tejani A.H., and Fine R.N. (Eds). Pediatric renal transplantation (1994), Wiley-Liss, New York 441-459
73. Maneatis T., Baptista J., Connelly K., et al. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 13 (2000) 1035-1044
74. Saenger P., Attie K.M., Martino-Nardi J., et al. Carbohydrate metabolism in children receiving growth hormone for 5 years. Chronic renal insufficiency compared with growth hormone deficiency, Turner syndrome, and idiopathic short stature. Genentech Collaborative Group. Pediatr Nephrol 10 (1996) 261-263
75. Turner H.H. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 23 (1938) 566-574
76. Ullrich O. Uber typische Kombinationsbilder multipler Abartung. Z Kinderheilkd 49 (1930) 271-276
77. Nielsen J., and Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet 87 (1991) 81-83
78. Ranke M.B., Pfluger H., Rosendahl W., et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 141 2 (1983) 81-88
79. Karlberg J., Albertsson-Wikland K., Nilsson K.O., et al. Growth in infancy and childhood in girls with Turner's syndrome. Acta Paediatr Scand 80 (1991) 1158-1165
80. Even L., Cohen A., Marbach N., et al. Longitudinal analysis of growth over the first 3 years of life in Turner's syndrome. J Pediatr 137 4 (2000) 460-464
81. Davenport M.L., Punyasavatsut N., Stewart P.W., et al. Growth failure in early life: an important manifestation of Turner syndrome. Horm Res 57 5-6 (2002) 157-164
82. Brook C.G., Murset G., Zachmann M., et al. Growth in children with 45,XO Turner's syndrome. Arch Dis Child 49 (1974) 789-795
83. Lyon A.J., Preece M.A., and Grant D.B. Growth curve for girls with Turner syndrome. Arch Dis Child 60 (1985) 932-935
84. Rochiccioli P., David M., Malpuech G., et al. Study of final height in Turner's syndrome: ethnic and genetic influences. Acta Paediatr 83 (1994) 305-308
85. Rongen-Westerlaken C., Corel L., van den Broeck J., et al. Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH treatment. Acta Paediatr 86 9 (1997) 937-942
86. Holl R.W., Kunze D., Etzrodt H., et al. Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediatr 153 (1994) 11-16
87. Massa G., Vanderschueren-Lodeweyckx M., and Malvaux P. Linear growth in patients with Turner syndrome: influence of spontaneous puberty and parental height. Eur J Pediatr 149 4 (1990) 246-250
88. Gravholt C.H., and Weis Naeraa R. Reference values for body proportions and body composition in adult women with Ullrich-Turner syndrome. Am J Med Genet 72 (1997) 403-408
89. Binder G., Fritsch H., Schweizer R., et al. Radiological signs of Leri-Weill dyschondrosteosis in Turner syndrome. Horm Res 55 2 (2001) 71-76
90. Kim J.Y., Rosenfeld S.R., and Keyak J.H. Increased prevalence of scoliosis in Turner syndrome. J Pediatr Orthop 21 (2001) 765-766
91. Elder D.A., Roper M.G., Henderson R.C., et al. Kyphosis in a Turner syndrome population. Pediatrics 109 (2002) e93
92. Ross J.L., Long L.M., Loriaux D.L., et al. Growth hormone secretory dynamics in Turner syndrome. J Pediatr 106 (1985) 202-206
93. Massarano A.A., Brook C.G., Hindmarsh P.C., et al. Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol. Arch Dis Child 64 (1989) 587-592
94. Massa G., Vanderschueren-Lodeweyckx M., Craen M., et al. Growth hormone treatment of Turner syndrome patients with insufficient growth hormone response to pharmacological stimulation tests. Eur J Pediatr 150 (1991) 460-463
95. Reiter J.C., Craen M., and Van V.G. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: relation to body weight and adiposity. Acta Endocrinol (Copenh) 125 (1991) 38-42
96. Pirazzoli P., Mazzanti L., Bergamaschi R., et al. Reduced spontaneous growth hormone secretion in patients with Turner's syndrome. Acta Paediatr 88 (1999) 610-613
97. Wit J.M., Massarano A.A., Kamp G.A., et al. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol (Copenh) 127 (1992) 7-12
98. Cianfarani S., Vaccaro F., Pasquino A.M., et al. Reduced growth hormone secretion in Turner syndrome: is body weight a key factor?. Horm Res 41 (1994) 27-32
99. Gravholt C.H., Frystyk J., Flyvbjerg A., et al. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am J Physiol Endocrinol Metab 280 (2001) E308-E314
100. Lebl J., Pruhova S., Zapletalova J., et al. IGF-I resistance and Turner's syndrome. J Pediatr Endocrinol Metab 14 (2001) 37-41
101. Rao E., Weiss B., Fukami M., et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 16 (1997) 54-63
102. Kosho T., Muroya K., Nagai T., et al. Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J Clin Endocrinol Metab 84 (1999) 4613-4621
103. Rappold G, Werner F, Blum WF, et al. Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet, in press.
104. Ogata T., and Matsuo N. Turner syndrome and female sex chromosome aberrations: deduction of the principal factors involved in the development of clinical features. Hum Genet 95 (1995) 607-629
105. Haverkamp F., Wolfle J., Zerres K., et al. Growth retardation in Turner syndrome: aneuploidy, rather than specific gene loss, may explain growth failure. J Clin Endocrinol Metab 84 (1999) 4578-4582
106. Buchanan C.R., Law C.M., and Milner R.D.G. Growth hormone in short, slowly growing children and those with Turner's syndrome. Arch Dis Child 62 (1987) 912-916
107. Rosenfeld R.G. Acceleration of growth in Turner syndrome patients treated with growth hormone: summary of three-year results. J Endocrinol Invest 12 (1989) 49-51
108. Vanderschueren-Lodeweyckx M., Massa G., Maes M., et al. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome. J Clin Endocrinol Metab 70 (1990) 122-126
109. Werther G.A. A multi-centre double-blind study of growth hormone and low-dose estrogen in Turner syndrome: an interim analysis. In: Ranke M.B., and Rosenfeld R.G. (Eds). Turner syndrome: growth promoting therapies (1991), Elsevier Science, Philadelphia
110. Cave C.B., Bryant J., and Milne R. Recombinant growth hormone in children and adolescents with Turner syndrome. Cochrane Database Syst Rev (2003) CD003887
111. Rosenfeld R.G., Attie K.M., Frane J., et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr 132 (1998) 319-324
112. Chernausek S.D., Attie K.M., Cara J.F., et al. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab 85 7 (2000) 2439-2445
113. Quigley C.A., Crowe B.J., Anglin D.G., et al. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 87 (2002) 2033-2041
114. Stephure D.K., and on behalf or the Canadian Pediatric Endocrine Group. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 90 (2005) 3360-3366
115. Chu C.E., Paterson W.F., Kelnar C.J., et al. Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner's syndrome. Acta Paediatr 86 (1997) 160-164
116. Dacou-Voutetakis C., Karavanaki-Karanassiou K., Petrou V., et al. The growth pattern and final height of girls with Turner syndrome with and without human growth hormone treatment. Pediatrics 101 (1998) 663-668
117. Taback S.P., and Van Vliet G. Growth hormone, adult height, and psychosocial outcome in Turner syndrome: the need for controlled studies. In: Albertsson-Wikland K., and Ranke M.B. (Eds). Turner syndrome in a life-span perspective (1994), Elsevier Science B.V., Amsterdam 183-190
118. Taback S.P., Collu R., Deal C.L., et al. Does growth-hormone supplementation affect adult height in Turner's syndrome?. Lancet 348 9019 (1996) 25-27
119. Rosenfield R.L., Devine N., Hunold J.J., et al. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 90 (2005) 6424-6430
120. Conway G.S. Oestrogen replacement in young women with Turner's syndrome. Clin Endocrinol (Oxf) 54 (2001) 157-158
121. Bondy C.A. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92 (2007) 10
122. Carel J.C., Elie C., Ecosse E., et al. Self-esteem and social adjustment in young women with Turner syndrome-influence of pubertal management and sexuality: population-based cohort study. J Clin Endocrinol Metab 91 (2006) 2972-2979
123. Davenport ML, Crowe BJ, Travers SH, et al. Growth hormone corrects early growth failure in Turner syndrome: results from the randomized, controlled, multi-center, 'Toddler Turner' study. Submitted for publication.
124. Nielsen J., Johansen K., and Yde H. The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinol (Copenh) 62 Suppl 2 (1969) 251-269
125. Caprio S., Boulware D., and Tamborlane V. Growth hormone and insulin interactions. Horm Res 38 Suppl 2 (1992) 47-49
126. Bakalov V.K., Cooley M.M., Quon M.J., et al. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 89 7 (2004) 3516-3520
127. Radetti G., Pasquino B., Gottardi E., et al. Insulin sensitivity in Turner's syndrome: influence of GH treatment. Eur J Endocrinol 151 3 (2004) 351-354
128. Wilson D.M., Frane J.W., Sherman B., et al. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr 112 (1988) 210-217
129. Weise M., James D., Leitner C.H., et al. Glucose metabolism in Ullrich Turner syndrome: long-term effects of therapy with human growth hormone. German Lilly UTS Study Group. Horm Res 39 (1993) 36-41
130. Sas T.C., de Muinck Keizer-Schrama S.M., Stijnen T., et al. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab 85 (2000) 769-775
131. Cutfield W.S., Wilton P., Bennmarker H., et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355 9204 (2000) 610-613
132. Abbott J., Hope K., Nair S., et al. Growth-hormone treatment and risk of diabetes. Lancet 2000 (1913) 355
133. Clayton P.E., and Cowell C.T. Safety issues in children and adolescents during growth hormone therapy-a review. Growth Horm IGF Res 10 6 (2000) 306-317
134. Kohno H., Kuromaru R., Ueyama N., et al. Growth hormone treatment and type 2 diabetes. Growth Horm IGF Res 11 (2001) 196-197
135. Tanaka T., Cohen P., Clayton P.E., et al. Diagnosis and management of growth hormone deficiency in childhood and adolescence-part 2: growth hormone treatment in growth hormone-deficient children. Growth Horm IGF Res 12 (2002) 323-341
136. Growth Hormone Research Society. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86 (2001) 1868-1870
137. Watkin P.M. Otological disease in Turner's syndrome. J Laryngol Otol 103 8 (1989) 731-738
138. Roush J, Quigley CA, Bryant CG, et al. Effect of GH treatment on ear disease in young girls with Turner syndrome (TS) [abstract 902]. Presented at the annual meeting of the Lawson Wilkins Pediatric Endocrine Society and Pediatric Academic Societies. San Francisco, May 1-4, 2004.
139. Allen D.B. Safety of human growth hormone therapy: current topics. J Pediatr 128 5 Pt 2 (1996) S8-S13
140. Blethen S.L., and Rundle A.C. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm Res 46 3 (1996) 113-116
141. Lowenstein E.J., Kim K.H., and Glick S.A. Turner's syndrome in dermatology. J Am Acad Dermatol 50 (2004) 767-776
142. Wyatt D. Melanocytic nevi in children treated with growth hormone. Pediatrics 104 4 Pt 2 (1999) 1045-1050
143. Lin A.E., Lippe B., and Rosenfeld R.G. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics 102 1 (1998) e12
144. Sybert V.P. Cardiovascular malformations and complications in Turner syndrome. Pediatrics 101 1 (1998) E11
145. van den Berg J., Bannink E.M., Wielopolski P.A., et al. Aortic distensibility and dimensions and the effects of growth hormone treatment in the turner syndrome. Am J Cardiol 97 11 (2006) 1644-1649
146. Belin V., Cusin V., Viot G., et al. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nat Genet 19 (1998) 67-69
147. Shears D.J., Vassal H.J., Goodman F.R., et al. Mutation and deletion of the pseudoautosomal gene SHOX cause Leri-Weill dyschondrosteosis. Nat Genet 19 (1998) 70-73
148. Rappold G.A., Fukami M., Niesler B., et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab 87 (2002) 1402-1406
149. Binder G., Ranke M.B., and Martin D.D. Auxology is a valuable instrument for the clinical diagnosis of SHOX haploinsufficiency in school-age children with unexplained short stature. J Clin Endocrinol Metab 88 (2003) 4891-4896
150. Blum WF, Crowe BJ, Quigley CA, et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: two year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab, 2007;92:219-28.
151. Falcinelli C., Iughetti L., Percesepe A., et al. SHOX point mutations and deletions in Leri-Weill dyschondrosteosis. J Med Genet 39 6 (2002) E33
152. Flanagan S.F., Munns C.F., Hayes M., et al. Prevalence of mutations in the short stature homeobox containing gene (SHOX) in Madelung deformity of childhood. J Med Genet 39 10 (2002) 758-763
153. Huber C., Rosilio M., Munnich A., et al. High incidence of SHOX anomalies in patients with short stature. J Med Genet 43 (2006) 735-739
154. Léri A., and Weill J. Une affection congenital et symetrique du development osseux: la dyschondrosteose. Bull Mém Soc Med Paris 35 (1929) 1491-1494
155. Ross J.L., Kowal K., Quigley C.A., et al. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Léri-Weill dyschondrosteosis and Turner syndrome. J Pediatr 147 (2005) 499-507
156. Clement-Jones M., Schiller S., Rao E., et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet 9 (2000) 695-702
157. Ellison J.W., Wardak Z., Young M.F., et al. PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Hum Mol Genet 6 (1997) 1341-1347
158. Rao E., Blaschke R.J., Marchini A., et al. The Léri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator. Hum Mol Genet 10 (2001) 3083-3091
159. Marchini A., Marttila T., Winter A., et al. The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes. J Biol Chem 279 (2004) 37103-37114
160. Munns C.J., Haase H.R., Crowther L.M., et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab 89 (2004) 4130-4135
161. Munns C.F., Glass I.A., LaBrom R., et al. Histopathological analysis of Léri-Weill dyschondrosteosis: disordered growth plate. Hand Surg 6 1 (2001) 13-23
162. Ogata T., Matsuo N., and Nishimura G. SHOX haploinsufficiency and overdosage: impact of gonadal function status. J Med Genet 38 1 (2001) 1-6
163. Niesler B., Fischer C., and Rappold G.A. The human SHOX mutation database. Hum Mutat 20 (2002) 338-341
164. Fischer C, Niesler B. Human short stature gene allelic variant database. Available at: www.shox.uni-hd.de. Accessed January 4, 2007.
165. Schiller S., Spranger S., Schechinger B., et al. Phenotypic variation and genetic heterogeneity in Leri-Weill syndrome. Eur J Hum Genet 8 1 (2000) 54-62
166. Munns C.F., Berry M., Vickers D., et al. Effect of 24 months of recombinant growth hormone on height and body proportions in SHOX haploinsufficiency. J Pediatr Endocrinol Metab 16 (2003) 997-1004
167. Binder G., Renz A., Martinez A., et al. SHOX haploinsufficiency and Léri-Weill dyschondrosteosis: prevalence and growth failure in relation to mutation, sex, and degree of wrist deformity. J Clin Endocrinol Metab 89 (2004) 4403-4408
168. Hediger M.L., Overpeck M.D., Maurer K.R., et al. Growth of infants and young children born small or large for gestational age: findings from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 152 (1998) 1225-1231
169. Lee P.A., Chernausek S.D., Hokken-Koelega A.C., et al. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics 111 (2003) 1253-1261
170. Wit J.M., Finken M.J., Rijken M., et al. Confusion around the definition of small for gestational age. Pediatr Endocrinol Rev 3 (2005) 52-53
171. Clayton PE, Cianfarani S, Czernichow P, et al. The child born small for gestational age (SGA): a consensus statement on management through to adulthood. J Clin Endocrinol Metab 2007, doi: 10.1210/jc. 2006-2017.
172. Hokken-Koelega A.C., De Ridder M.A., Lemmen R.J., et al. Children born small for gestational age: do they catch up?. Pediatr Res 38 2 (1995) 267-271
173. Karlberg J., and Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 38 5 (1995) 733-739
174. Karlberg JP, Albertsson-Wikland K, Kwan EY, et al. The timing of early postnatal catch-up growth in normal, full-term infants born short for gestational age. Horm Res 1997;48(Suppl 1):17-24.
175. Albertsson-WIkland K., Boguszewski M., and Karlberg J. Children born small for gestational age: postnatal growth and hormonal status. Horm Res 49 Suppl 2 (1998) 7-13
176. Karlberg J., Albertsson-Wikland K., Kwan C.W., et al. Early spontaneous catch-up growth. J Pediatr Endocrinol 15 Suppl 5 (2002) 1243-1255
177. Leger J., Levy-Marchal C., Bloch J., et al. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ 315 7104 (1997) 341-347
178. Chatelain P., Job J.C., Blanchard J., et al. Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. J Clin Endocrinol Metab 78 6 (1994) 1454-1460
179. Albertsson-Wikland K., and Karlberg J. Postnatal growth of children born small for gestational age. Acta Paediatr Suppl 423 (1997) 193-195
180. Leger J., Limoni C., Collin D., et al. Prediction factors in the determination of final height in subjects born small for gestational age. Pediatr Res 43 (1998) 808-812
181. de Zegher F., Francois I., Van H.M., et al. Clinical review 89: small as fetus and short as child: from endogenous to exogenous growth hormone. J Clin Endocrinol Metab 82 (1997) 2021-2026
182. Vicens-Calvet E., Espadero R.M., and Carrascosa A. Spanish SGA Collaborative Group. Small for gestational age. Longitudinal study of the pubertal growth spurt in children born small for gestational age without postnatal catch-up growth. J Pediatr Endocrinol Metab 15 (2002) 381-388
183. Hokken-Koelega A.C.S. Timing of puberty and fetal growth. Best Pract Res Clin Endocrinol Metab 16 (2002) 65-71
184. Job J.C., and Rolland A. Natural history of intrauterine growth retardation: pubertal growth and adult height. Arch Fr Pediatr 43 5 (1986) 301-306
185. Davies P.S.W., Valley R., and Preece M.A. Adolescent growth and pubertal progression in the Silver-Russell syndrome. Arch Dis Child 64 (1988) 130-135
186. Lazar L., Pollak U., Kalter-Leibovici O., et al. Pubertal course of persistently short children born small for gestational age (SGA) compared with idiopathic short children born appropriate for gestational age (AGA). Eur J Endocrinol 149 (2003) 425-432
187. Rogol A. 2006. Growth, puberty and therapeutic interventions [abstract S1-15]. Presented at the 45th European Society for Pediatric Endocrinology annual meeting. Rotterdam, June 30-July 3, 2006.
188. Wollmann H.A. Intrauterine growth restriction: definition and etiology. Horm Res 49 Suppl 2 (1998) 1-6
189. Lassarre C., Hardouin S., Daffos F., et al. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 29 (1991) 219-225
190. de Waal W.J., Hokken-Koelega A.C., Stijnen T., et al. Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone. Clin Endocrinol (Oxf) 41 (1994) 621-630
191. Boguszewski M., Rosberg S., and Albertsson-Wikland K. Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. J Clin Endocrinol Metab 80 (1995) 2599-2606
192. Ogilvy-Stuart A.L., Hands S.J., Adcock C.J., et al. Insulin, insulin-like growth factor I (IGF-I), IGF-binding protein-1, growth hormone, and feeding in the newborn. J Clin Endocrinol Metab 83 (1998) 3550-3557
193. Audi L, Esteban C, Espadero R, et al. D-3 growth hormone receptor polymorphism (d3-GHR) genotype frequencies differ between short small for gestational age children (SGA) (n = 247) and a control population with normal adult height (n = 289) (CPNAH) [abstract S1-15]. Presented at the 45th European Society for Pediatric Endocrinology annual meeting. Rotterdam, June 30-July 3, 2006.
194. Jensen RB, Viewerth S, Larsen T, et al. High prevalence of d3-growth hormone gene polymorphism in adolescents born SGA/IUGR: association with intrauterine growth velocity, birth weight, postnatal catch-up growth and near-final height [abstract FC1-42]. Presented at the 45th European Society for Pediatric Endocrinology annual meeting. Rotterdam, June 30-July 3, 2006.
195. Woods K.A., Camacho-Hubner C., Savage M.O., et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335 (1996) 1363-1367
196. Bonapace G., Concolino D., Formicola S., et al. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 40 (2003) 913-917
197. Walenkamp M.J., Karperien M., Pereira A.M., et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 90 (2005) 2855-2864
198. Cianfarani S., Maiorana A., Geremia C., et al. Blood glucose concentrations are reduced in children born small for gestational age (SGA), and thyroid-stimulating hormone levels are increased in SGA with blunted postnatal catch-up growth. J Clin Endocrinol Metab 88 (2003) 2699-2705
199. Tenhola S., Halonen P., Jaaskelainen J., et al. Serum markers of GH and insulin action in 12-year-old children born small for gestational age. Eur J Endocrinol 152 (2005) 335-340
200. Arends N., Johnston L., and Hokken-Kolega A. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 87 (2002) 2720
201. Vaessen N., Janssen J.A., Heutink P., et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 359 (2002) 1036-1037
202. Johnston L.B., Dahlgren J., Leger J., et al. Association between insulin-like growth factor I (IGF-I) polymorphisms, circulating IGF-I, and pre- and postnatal growth in two European small for gestational age populations. J Clin Endocrinol Metab 88 (2003) 4805-4810
203. Netchine I, Rossignol S, Dufourg MNC, et al. Epimutation of the telomeric domain on chromosome 11p15 is a major and specific cause of Silver-Russell syndrome [abstract HA-8]. Presented at the 45th European Society for Pediatric Endocrinology annual meeting. Rotterdam, June 30-July 3, 2006.
204. Abuzzahab M.J., Schneider A., Goddard A., et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 349 (2003) 2211-2222
205. Tanner J.M., and Ham T.J. Low birthweight dwarfism with asymmetry (Silver's syndrome): treatment with human growth hormone. Arch Dis Child 44 (1969) 231-243
206. Lee P.A., Blizzard R.M., Cheek D.B., et al. Growth and body composition in intrauterine growth retardation (IUGR) before and during human growth hormone administration. Metabolism 23 (1974) 913-919
207. de Zegher F., Du Caju M.V., Heinrichs C., et al. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 84 (1999) 1558-1561
208. Hokken-Koelega A., van Pareren Y., Arends N., et al. Efficacy and safety of long-term continuous growth hormone treatment of children born small for gestational age. Horm Res 62 Suppl 3 (2004) 149-154
209. de Zegher F., and Hokken-Koelega A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. Pediatrics 115 (2005) e458-e462
210. Rosilio M., Carel J.C., Ecosse E., et al. Adult height of prepubertal short children born small for gestational age treated with GH. Eur J Endocrinol 152 6 (2005) 835-843
211. de Zegher F., Ong K.K., Ibanez L., et al. Growth hormone therapy in short children born small for gestational age. Horm Res 65 Suppl 3 (2006) 145-152
212. Genotropin (somatropin [rDNA origin] for injection). [prescribing information] (2006), Pfizer, Inc., New York
213. Job J.C., Chaussain J.L., Job B., et al. Follow-up of three years of treatment with growth hormone and of one post-treatment year, in children with severe growth retardation of intrauterine onset. Pediatr Res 39 (1996) 354-359
214. Ong K., Beardsall, and de Zegher F. Growth hormone therapy in short children born small for gestational age. Early Hum Devel 81 (2005) 973-980
215. Norditropin (somatropin [rDNA origin] for injection) [statement of product characteristics]. EMEA/CPMP/1404/03. Available at: http://www.emea.eu.int/pdfs/human/referral/norditropin/347803en.pdf. Accessed January 4, 2007.
216. Carel J.C., Chatelain P., Rochiccioli P., et al. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab 88 (2003) 1587-1593
217. Ranke M.B., Lindberg A., Cowell C.T., et al. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 88 (2003) 125-131
218. Binder G., Baur F., Schweizer R., et al. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91 (2006) 659-664
219. de Zegher F., Albertsson-Wikland K., Wollmann H.A., et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 85 (2000) 2816-2821
220. Fjellestad-Paulsen A., Simon D., and Czernichow P. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment. J Clin Endocrinol Metab 89 (2004) 1234-1239
221. Barker D.J., Hales C.N., Fall C.H., et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36 (1993) 62-67
222. Hofman P.L., Cutfield W.S., Robinson E.M., et al. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 82 (1997) 402-406
223. Crowther N.J., Cameron N., Trusler J., et al. Association between poor glucose tolerance and rapid post natal weight gain in seven-year old children. Diabetologia 41 (1998) 1163-1167
224. Jaquet D., Gaboriau A., Czernichow P., et al. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. J Clin Endocrinol Metab 85 (2000) 1401-1406
225. Veening M.A., Van Weissenbruch M.M., and Delemarre-Van De Waal H.A. Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J Clin Endocrinol Metab 87 (2002) 4657-4661
226. Soto N., Bazaes R.A., Pena V., et al. Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. J Clin Endocrinol Metab 88 (2003) 3645-3650
227. de Zegher F., Maes M., Gargosky S.E., et al. High-dose growth hormone treatment of short children born small for gestational age. J Clin Endocrinol Metab 81 5 (1996) 1887-1892
228. Sas T., Mulder P., Aanstoot H.J., et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf) 54 2 (2001) 243-251
229. de Zegher F., Ong K., van Helvoirt M., et al. High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab 87 1 (2002) 148-151
230. van Pareren Y., Mulder P., Houdijk M., et al. Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestational age. J Clin Endocrinol Metab 88 1 (2003) 347-353
231. Wilton P. Adverse events during GH treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey. In: Ranke M.B., and Wilton P. (Eds). Growth hormone therapy in KIGS. 10 years' experience (1999), Johann Ambrosius Barth Verlag, Heidelberg (Germany) 349-364
232. Cutfield W.S., Lindberg A., Rapaport R., et al. Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res 65 Suppl 3 (2006) 153-159
233. Sas T., Mulder P., and Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 85 10 (2000) 3786-3792
234. Czernichow P. Treatment with growth hormone in short children born with intrauterine growth retardation. Endocrine 15 1 (2001) 39-42
235. Simeoni U., and Zetterstrom R. Long-term circulatory and renal consequences of intrauterine growth restriction. Acta Paediatr 94 7 (2005) 819-824
236. Chatelain P. Children born with intra-uterine growth retardation (IUGR) or small for gestational age (SGA): long term growth and metabolic consequences. Endocr Regul 34 1 (2000) 33-36
237. Levy-Marchal C., and Czernichow P. Small for gestational age and the metabolic syndrome: which mechanism is suggested by epidemiological and clinical studies?. Horm Res 65 Suppl 3 (2006) 123-130
238. Ranke M.B. Towards a consensus on the definition of idiopathic short stature. Horm Res 45 Suppl 2 (1996) 64-66
239. Humatrope (somatropin [rDNA origin] for injection). {prescribing information} (2006), Eli Lilly and Company, Indianapolis (IN)
240. Finkelstein B.S., Silvers J.B., Marrero U., et al. Insurance coverage, physician recommendations, and access to emerging treatments: growth hormone therapy for childhood short stature. JAMA 279 9 (1998) 663-668
241. Price D.A. Spontaneous adult height in patients with idiopathic short stature. Horm Res 45 Suppl 2 (1996) 59-63
242. Wit J.M., Kamp G.A., and Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res 39 (1996) 295-302
243. Buchlis J.G., Irizarry L., Crotzer B.C., et al. Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure. J Clin Endocrinol Metab 83 (1998) 1075-1079
244. Crowne E.C., Shalet S.M., Wallace W.H., et al. Final height in boys with untreated constitutional delay in growth and puberty. Arch Dis Child 65 (1990) 1109-1112
245. Bramswig J.H., Fasse M., Holthoff M.L., et al. Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: accuracy of five different methods of height prediction. J Pediatr 117 (1990) 886-891
246. Ranke M.B., Grauer M.L., Kistner K., et al. Spontaneous adult height in idiopathic short stature. Horm Res 44 4 (1995) 152-157
247. Hintz R.L., Attie K.M., Baptista J., et al. Effect of growth hormone treatment on adult height of children with idiopathic short stature. N Engl J Med 340 (1999) 502-507
248. Rekers-Mombarg L.T., Kamp G.A., Massa G.G., et al. Influence of growth hormone treatment on pubertal timing and pubertal growth in children with idiopathic short stature. Dutch Growth Hormone Working Group. J Pediatr Endocrinol Metab 12 (1999) 611-622
249. Leschek E.W., Rose S.R., Yanovski J.A., et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 89 (2004) 3140-3148
250. Counts D., and Palese T. A novel polymorphism in exon 4 of the growth hormone gene and association of short stature with a known 5′ UTR polymorphism. J Endocr Genet 2 (2001) 55-60
251. Horan M., Millar D.S., Hedderich J., et al. Human growth hormone 1 (GH1) gene expression: complex haplotype-dependent influence of polymorphic variation in the proximal promoter and locus control region. Hum Mutat 21 (2003) 408-423
252. Millar D.S., Lewis M.D., Horan M., et al. Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Hum Mutat 4 (2003) 424-440
253. Spiliotis B.E., August G.P., Hung W., et al. Growth hormone neurosecretory dysfunction. A treatable cause of short stature. JAMA 251 (1984) 2223-2230
254. Zadik Z., Chalew S.A., Raiti S., et al. Do short children secrete insufficient growth hormone?. Pediatrics 76 (1985) 355-360
255. Spadoni G.L., Cianfarani S., Bernardini S., et al. Twelve-hour spontaneous nocturnal growth hormone secretion in growth retarded patients. Clin Pediatr (Phila) 27 (1988) 473-478
256. Rogol A.D., Blethen S.L., Sy J.P., et al. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?. Clin Endocrinol (Oxf) 58 (2003) 229-237
257. Blair J.C., Camacho-Hubner C., Miraki M.F., et al. Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clin Endocrinol (Oxf) 60 (2004) 163-168
258. Besson A., Salemi S., Deladoey J., et al. Short stature caused by a biologically inactive mutant growth hormone (GH-C53S). J Clin Endocrinol Metab 90 (2005) 2493-2499
259. Pantel J., Legendre M., Cabrol S., et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 116 3 (2006) 760-768
260. Carlsson L.M., Attie K.M., Compton P.G., et al. Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study. J Clin Endocrinol Metab 78 (1994) 1325-1330
261. Mauras N., Carlsson L.M., Murphy S., et al. Growth hormone-binding protein levels: studies of children with short stature. Metabolism 43 (1994) 357-359
262. Goddard A.D., Covello R., Luoh S.M., et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 333 (1995) 1093-1098
263. Goddard A.D., Dowd P., Chernausek S., et al. Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature. J Pediatr 131 (1997) S51-S55
264. Rosenbloom A.L. Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction. Endocrine 12 (2000) 107-119
265. Salerno M., Balestrieri B., Matrecano E., et al. Abnormal GH receptor signaling in children with idiopathic short stature. J Clin Endocrinol Metab 86 (2001) 3882-3888
266. Bonioli E., Taro M., Rosa C.L., et al. Heterozygous mutations of growth hormone receptor gene in children with idiopathic short stature. Growth Horm IGF Res 15 (2005) 405-410
267. Sjoberg M., Salazar T., Espinosa C., et al. Study of GH sensitivity in Chilean patients with idiopathic short stature. J Clin Endocrinol Metab 86 (2001) 4375-4381
268. Savage M.O., Attie K.M., David A., et al. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2 (2006) 395-407
269. Bussieres L., Souberbielle J.C., Pinto G., et al. The use of insulin-like growth factor 1 reference values for the diagnosis of growth hormone deficiency in prepubertal children. Clin Endocrinol (Oxf) 52 (2000) 735-739
270. Mauras N., Walton P., Nicar M., et al. Growth hormone stimulation testing in both short and normal statured children: use of an immunofunctional assay. Pediatr Res 48 (2000) 614-618
271. Domene H.M., Bengolea S.V., Martinez A.S., et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 350 (2004) 570-577
272. Domene H.M., Bengolea S.V., Jasper H.G., et al. Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest 28 (2005) 43-46
273. Hwa V., Haeusler G., Pratt K.L., et al. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 91 (2006) 1826-1831
274. Olney R.C., Bukulmez H., Bartels C.F., et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab 91 4 (2006) 1229-1232
275. De Bellis A., Salerno M., Conte M., et al. Antipituitary antibodies recognizing growth hormone (GH)-producing cells in children with idiopathic GH deficiency and in children with idiopathic short stature. J Clin Endocrinol Metab 91 7 (2006) 2484-2489
276. Wudy S.A., Hagemann S., Dempfle A., et al. Children with idiopathic short stature are poor eaters and have decreased body mass index. Pediatrics 116 (2005) e52-e57
277. Finkelstein B.S., Imperiale T.F., Speroff T., et al. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch Pediatr Adolesc Med 156 3 (2002) 230-240
278. Food and Drug Administration. Transcript of the meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, September 28-29, 1987. Rockville (MD): Food and Drug Administration; 1987. p. 169.
279. Ross J.L., Sandberg D.E., Rose S.R., et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab 89 10 (2004) 4873-4878
280. Wit J.M., Rekers-Mombarg L.T., Cutler G.B., et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr 146 (2005) 45-53
281. Quigley C.A., Gill A.M., Crowe B.J., et al. Safety of GH treatment in patients with idiopathic short stature. J Clin Endocrinol Metab 90 (2005) 5188-5196
282. Crowe B.J., Rekers-Mombarg L.T., et al. European Idiopathic Short Stature Group. Effect of growth hormone dose on bone maturation and puberty in children with idiopathic short stature. J Clin Endocrinol Metab 91 1 (2006) 169-175
283. Leschek E.W., Troendle J.F., Yanovski J.A., et al. Effect of growth hormone treatment on testicular function, puberty, and adrenarche in boys with non-growth hormone-deficient short stature: a randomized, double-blind, placebo-controlled trial. J Pediatr 138 3 (2001) 406-410
284. Lindgren A.C., Chatelain P., Lindberg A., et al. Normal progression of testicular size in boys with idiopathic short stature and isolated growth hormone deficiency treated with growth hormone: experience from the KIGS. Horm Res 58 (2002) 83-87
285. Darendeliler F., Ranke M.B., Bakker B., et al. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database). Horm Res 63 (2005) 40-47
286. Bryant J., Cave C., and Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 27 (2003) CD004440
287. Weise K.L., and Nahata M.C. Growth hormone use in children with idiopathic short stature. Ann Pharmacother 38 (2004) 1460-1468
288. Kemp S.F., Kuntze J., Attie K.M., et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 90 (2005) 5247-5253
289. Ranke M.B., Schweizer R., Elmlinger M.W., et al. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm Res 55 3 (2001) 115-124
290. Park P., and Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 15 Suppl A (2005) S13-S20
291. Wit J.M., and Rekers-Mombarg L.T. Dutch Growth Hormone Advisory Group. Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J Clin Endocrinol Metab 87 2 (2002) 604-611
292. Blum W.F., Machinis K., Shavrikova E.P., et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab 91 (2006) 4171-4174
293. Carrascosa A., Esteban C., Espadero R., et al., for the Spanish SGA Study Group. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab 91 9 (2006) 3281-3286
294. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
295. Saenger P., Attie K.M., Martino-Nardi J., et al. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. J Clin Endocrinol Metab 83 (1998) 3115-3120
296. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for growth hormone use in adults and children-2003 Update. Endocr Pract 9 1 (2003) 65-76
297. Wilson T.A., Rose S.R., Cohen P., et al., for the The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 143 4 (2003) 415-421
298. Hindmarsh P.C., and Cole T.J. Evidence-based growth hormone therapy prediction models. J Pediatr Endocrinol Metab 13 Suppl 6 (2000) 1359-1364
299. Ranke M.B. New paradigms for growth hormone treatment in the 21st century: prediction models. J Pediatr Endocrinol 13 Suppl 6 (2000) 1365-1369
300. Blum WF, Shavrikova EP, Keller A, et al. New methods for adult height prediction in children with idiopathic short stature [abstract]. Presented at the Endocrine Society's 87th Annual Meeting. San Diego, CA, June 4-7, 2005.
301. Peyrat J.P., Bonneterre J., Hecquet B., et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A (1993) 492-497
302. Bruning P.F., van D.J., Bonfrer J.M., et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62 (1995) 266-270
303. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 (1998) 1393-1396
304. Mantzoros C.S., Tzonou A., Signorello L.B., et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76 (1997) 1115-1118
305. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
306. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90 (1998) 911-915
307. Brunner J.E., Johnson C.C., Zafar S., et al. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol (Oxf) 32 (1990) 65-71
308. Ron E., Gridley G., Hrubec Z., et al. Acromegaly and gastrointestinal cancer. Cancer 68 (1991) 1673-1677
309. Jenkins P.J., Fairclough P.D., Richards T., et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 47 (1997) 17-22
310. Kaaks R., Toniolo P., Akhmedkhanov A., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92 (2000) 1592-1600
311. Ma J., Pollak M., Giovannucci E., et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 10 Suppl A (2000) S28-S29
312. Yu H., Spitz M.R., Mistry J., et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 (1999) 151-156
313. Lukanova A., Toniolo P., Akhmedkhanov A., et al. A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 92 (2001) 888-892
314. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 (2000) 215-244
315. Furstenberger G., and Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol 3 (2002) 298-302
316. Ali O., Cohen P., and Lee K.W. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 35 (2003) 726-733
317. Ogilvy-Stuart A.L., and Gleeson H. Cancer risk following growth hormone use in childhood: implications for current practice. Drug Saf 27 (2004) 369-382
318. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
319. Sperling M.A., Saenger P.H., Hintz R., et al. Growth hormone treatment and neoplasia-coincidence or consequence?. J Clin Endocrinol Metab 87 (2002) 5351-5352
320. Wang H.J., Geller F., Dempfle A., et al. Ghrelin receptor gene: indentification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with normal stature. J Clin Endocrinol Metab 89 1 (2004) 157-162
321. Lewis M.D., Horan M., Millar D.S., et al. A novel dysfunction growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway. J Clin Endocrinol Metab 89 3 (2004) 1068-1075
322. Takahashi Y., Shirono H., Arisaka O., et al. Biologically inactive growth hormone caused by an amino acid substitution. J Clin Invest 100 5 (1997) 1156-1165
323. Sjoberg M., Salazar T., Espinosa C., et al. Study of GH sensitivity in Chilean patients with idiopathic stature. J Clin Endocrinol Metab 86 9 (2001) 4375-4381
324. Sanchez J.E., Perera E., Baumbach L., et al. Growth hormone receptor mutations in children with idiopathic short stature. J Clin Endocrinol Metab 83 11 (1998) 4079-4083
325. Ayling R.M., Ross R.J., Towner P., et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nature Genet 16 1 (1997) 13-14
326. Ayling R.M., Ross R.J., Towner P., et al. New growth hormone receptor exon 9 mutation causes genetic short stature. Acta Paediatrica Suppl 88 428 (1999) 168-172
327. Kofoed E.M., Hwa V., Little B., et al. Growth hormone insensitivity associated with a Stat5b mutation. N Engl J Med 349 12 (2003) 1139-1147
328. Kawashima Y., Kanzaki S., Yang F., et al. Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 90 8 (2005) 4679-4687